MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma

Initial MRIs from 50 subjects with diffuse intrinsic pontine gliomas recruited for a prospective clinical trial before treatment were analyzed. Retrospective imaging analyses included FLAIR/T2 tumor volume, tumor volume enhancing, the presence of cyst and/or necrosis, median, mean, mode, skewness, kurtosis of ADC tumor volume based on FLAIR, and enhancement at baseline. Molecular subgroups based on EGFR and MGMT mutations were established. Histone mutations were also determined (H3F3A, HIST1H3B, HIST1H3C). Enhancing tumor volume was near-significantly different across molecular subgroups, after accounting for the false discovery rate. Tumor volume enhancing, median, mode, skewness, and kurtosis ADC T2-FLAIR/T2 were significantly different between patients with H3F3A and HIST1H3B/C mutations. BACKGROUND AND PURPOSE: Recent advances in molecular techniques have characterized distinct subtypes of diffuse intrinsic pontine gliomas. Our aim was the identification of MR imaging correlates of these subtypes. MATERIALS AND METHODS: Initial MRIs from subjects with diffuse intrinsic pontine gliomas recruited for a prospective clinical trial before treatment were analyzed. Retrospective imaging analyses included FLAIR/T2 tumor volume, tumor volume enhancing, the presence of cyst and/or necrosis, median, mean, mode, skewness, kurtosis of ADC tumor volume based on FLAIR, and enhancement at baseline. Molecular subgroups based on EGFR and MGMT mutations were established. Histone mutations were also determined (H3F3A, HIST1H3B, HIST1H3C). Univariate Cox proportional hazards regression was used to test the association of imaging predictors with overall and progression-free survival. Wilcoxon rank sum, Kruskal-Wallis, and Fisher exact tests were used to compare imaging measures among groups. RESULTS: Fifty patients had biopsy and MR imaging. The median age at trial registration was 6 years (range, 3.3–17.5 years); 52% were female. On the basis of immunohistochemical results, 48 patients were assigned to 1 of 4 subgroups: 28 in MGMT–/epidermal growth factor receptor (EGFR)–, 14 in MGMT–/EGFR+, 3 in MGMT+/EGFR–, and 3 in MGMT+/EGFR+. Twenty-three patients had histone mutations in H3F3A, 8 in HIST1H3B, and 3 in HIST1H3C. Enhancing tumor volume was near-significantly different across molecular subgroups (P = .04), after accounting for the false discovery rate. Tumor volume enhancing, median, mode, skewness, and kurtosis ADC T2-FLAIR/T2 were significantly different (P ≤ .048) between patients with H3F3A and HIST1H3B/C mutations. CONCLUSIONS: MR imaging features including enhancement and ADC histogram parameters are correlated with molecular subgroups and mutations in children with diffuse intrinsic pontine gliomas.

[1]  M. Aboian,et al.  Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis , 2019, American Journal of Neuroradiology.

[2]  Ninon Burgos,et al.  New advances in the Clinica software platform for clinical neuroimaging studies , 2019 .

[3]  Vincent Frouin,et al.  Can Structural MRI Radiomics Predict DIPG Histone H3 Mutation and Patient Overall Survival at Diagnosis Time? , 2019, 2019 IEEE EMBS International Conference on Biomedical & Health Informatics (BHI).

[4]  Yuanzhong Yang,et al.  Noninvasive assessment of H3 K27M mutational status in diffuse midline gliomas by using apparent diffusion coefficient measurements. , 2019, European journal of radiology.

[5]  T. MacDonald,et al.  Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma , 2018, Neuro-oncology.

[6]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[7]  M. Kool,et al.  Magnetic resonance imaging surrogates of molecular subgroups in atypical teratoid/rhabdoid tumor , 2018, Neuro-oncology.

[8]  S. Khatua,et al.  Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Vincent Frouin,et al.  Computation of reliable textural indices from multimodal brain MRI: suggestions based on a study of patients with diffuse intrinsic pontine glioma , 2018, Physics in medicine and biology.

[10]  S. Picton,et al.  Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis , 2017, Journal of Neuro-Oncology.

[11]  S. Vajapeyam,et al.  Correlation of 18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium , 2017, The Journal of Nuclear Medicine.

[12]  M. Aboian,et al.  Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation , 2017, American Journal of Neuroradiology.

[13]  C. Stevenson,et al.  Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas : A Review , 2016 .

[14]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[15]  M. Prados,et al.  Biopsy for diffuse intrinsic pontine glioma: a reappraisal. , 2016, Journal of neurosurgery. Pediatrics.

[16]  A. Panigrahy,et al.  Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. , 2016, Neuro-oncology.

[17]  P. Varlet,et al.  Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes , 2015, Acta Neuropathologica.

[18]  F. Barkhof,et al.  Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. , 2014, Neuro-oncology.

[19]  C. Hawkins,et al.  Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications , 2014, Acta Neuropathologica.

[20]  K. Yeom,et al.  MRI Surrogates for Molecular Subgroups of Medulloblastoma , 2014, American Journal of Neuroradiology.

[21]  K. Yeom,et al.  Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma , 2014, Journal of Neuro-Oncology.

[22]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[23]  P. Kearns,et al.  Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – Results of a United Kingdom phase II trial (CNS 2007 04) , 2013, European journal of cancer.

[24]  William D. Dunn,et al.  MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. , 2013, Radiology.

[25]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[26]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[27]  I. Pollack,et al.  MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). , 2011, Neuro-oncology.

[28]  W. Reddick,et al.  Quantitative Diffusion-Weighted and Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Analysis of T2 Hypointense Lesion Components in Pediatric Diffuse Intrinsic Pontine Glioma , 2011, American Journal of Neuroradiology.

[29]  M. Schocke,et al.  ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma , 2011, Neuroradiology.

[30]  A. Panigrahy,et al.  Apparent Diffusion and Fractional Anisotropy of Diffuse Intrinsic Brain Stem Gliomas , 2010, American Journal of Neuroradiology.

[31]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[32]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[33]  Paul S Mischel,et al.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. , 2008, Radiology.

[34]  M. Prados,et al.  Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. , 1996, Pediatric neurosurgery.

[35]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[36]  Commentary on “ Histone H 3 F 3 A and HIST 1 H 3 B K 27 M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes , 2022 .